Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Matthay

Showing results (281-290 of 316) with videos related to

Pageof 32
Sort By:
Pediatric Blood & Cancer|April 7, 2017
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupSteven G DuBois, Rajen Mody, Arlene Naranjo, et al.
Pediatric Blood & Cancer|June 1, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531Erin K Barr, Arlene Naranjo, Clare J Twist, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastomaAlexei L Polishchuk, Richard Li, Christine Hill-Kayser, et al.
Pediatric Blood & Cancer|April 20, 2016
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca, Samuel L Volchenboum, Hwangeui Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) TrialSteven G DuBois, Araz Marachelian, Elizabeth Fox, et al.
International Journal of Cancer|March 27, 2001
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplificationD Plantaz, J Vandesompele, N Van Roy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2012
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay, Brian Weiss, Judith G Villablanca, et al.
British Journal of Cancer|January 10, 2024
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trialMichael D Hogarty, David S Ziegler, Andrea Franson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2017
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1Gregory A Yanik, Marguerite T Parisi, Arlene Naranjo, et al.
British Journal of Cancer|September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectG Schleiermacher, V Mosseri, W B London, et al.
Pageof 32

Showing results (281-290 of 316) with videos related to

Sort By:
Pageof 32
Pediatric Blood & Cancer|April 7, 2017
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupSteven G DuBois, Rajen Mody, Arlene Naranjo, et al.
Pediatric Blood & Cancer|June 1, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531Erin K Barr, Arlene Naranjo, Clare J Twist, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastomaAlexei L Polishchuk, Richard Li, Christine Hill-Kayser, et al.
Pediatric Blood & Cancer|April 20, 2016
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca, Samuel L Volchenboum, Hwangeui Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) TrialSteven G DuBois, Araz Marachelian, Elizabeth Fox, et al.
International Journal of Cancer|March 27, 2001
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplificationD Plantaz, J Vandesompele, N Van Roy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2012
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay, Brian Weiss, Judith G Villablanca, et al.
British Journal of Cancer|January 10, 2024
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trialMichael D Hogarty, David S Ziegler, Andrea Franson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2017
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1Gregory A Yanik, Marguerite T Parisi, Arlene Naranjo, et al.
British Journal of Cancer|September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectG Schleiermacher, V Mosseri, W B London, et al.
Pageof 32